Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Snaps Up Memory, Gains CNS Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss drugmaker gains partnered compounds in Alzheimer’s and schizophrenia via $50 million deal.

You may also be interested in...



Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors

Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.

Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors

Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.

Tarnished HALO For Targacept/AstraZeneca Schizophrenia Drug

Partners halt development of AZD3480 in schizophrenia after Phase II failure, but will wait for ADHD trial before deciding the fate of the compound.

Related Content

Topics

UsernamePublicRestriction

Register

PS067067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel